← Leaderboards
Slobodan Paessler
University Of Texas Medical Br Galveston
$18,721,420
Attributed
$26,929,356
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,929,356 · 10
By mechanism
R01$16,681,824 · 4
UC7$7,110,414 · 1
R56$1,478,385 · 2
T32$775,235 · 1
K08$445,298 · 1
R21$438,200 · 1
Top collaborators
- Juan C. De La Torre6 shared
- Frank R. Jones5 shared
- Yuying Liang5 shared
- Hinh Ly5 shared
- Peter C. Melby5 shared
- Luis Martinez-Sobrido2 shared
- Igor S. Lukashevich1 shared
Most similar at University Of Texas Medical Br Galveston
Same institution · by research overlap
- Scott C Weaver$56,593,623
- David H Walker$27,320,724
- Charles F Fulhorst$4,357,752
- Elena I Frolova$7,924,153
- Nigel Bourne$10,520,495
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionBaseAnimalsAnimal ModelFutureVaccinesVirus DiseasesPreventVirusPathogenBiologicalImmuneTechnologyViralAfricaPropertyIn VivoTissuesArenavirusViral Hemorrhagic FeversLassa VirusMediatingSafetyExhibits
Grant awards (39)
Physician-Scientist Training in Emerging Infectious Diseases$207,348
T32 · FY2025 · AI
Exploration of D-Glucose and D-Mannose Metabolism to Target arenaviruses$626,423
R56 · FY2024 · AI · contact PI
Physician-Scientist Training in Emerging Infectious Diseases$102,304
T32 · FY2024 · AI
Physician-Scientist Training in Emerging Infectious Diseases$186,789
T32 · FY2023 · AI
Sequelae of Lassa Fever$727,278
R01 · FY2022 · AI · contact PI
Physician-Scientist Training in Emerging Infectious Diseases$189,338
T32 · FY2022 · AI
Sequelae of Lassa Fever$734,826
R01 · FY2021 · AI · contact PI
Mechanism of Lassa fever virus Z protein in immune suppression and viral virulence$730,564
R01 · FY2021 · AI
Physician-Scientist Training in Emerging Infectious Diseases$89,456
T32 · FY2021 · AI
Sequelae of Lassa Fever$742,240
R01 · FY2020 · AI · contact PI
Mechanism of Lassa fever virus Z protein in immune suppression and viral virulence$739,394
R01 · FY2020 · AI
Mechanism of Lassa fever virus Z protein in immune suppression and viral virulence$749,142
R01 · FY2019 · AI
Sequelae of Lassa Fever$748,628
R01 · FY2019 · AI · contact PI
Sequelae of Lassa Fever$158,000
R01 · FY2019 · AI · contact PI
Reverse Genetics To Forward The Pan-Lassa Fever Vaccine Lead Candidate ML29$851,962
R56 · FY2018 · AI · contact PI
Mechanism of Lassa fever virus Z protein in immune suppression and viral virulence$757,888
R01 · FY2018 · AI
Sequelae of Lassa Fever$757,470
R01 · FY2018 · AI · contact PI
Development of a Universal Influenza Vaccine$734,209
R01 · FY2018 · AI
Mechanism of Lassa fever virus Z protein in immune suppression and viral virulence$782,328
R01 · FY2017 · AI
Development of a Universal Influenza Vaccine$612,096
R01 · FY2017 · AI
Development of a Universal Influenza Vaccine$594,261
R01 · FY2016 · AI
Development of a safe and valid surrogate to study Lassa virus$192,850
R21 · FY2016 · AI · contact PI
Development of a Universal Influenza Vaccine$1,121,460
R01 · FY2015 · AI
Recombinant life attenuated vaccine against Argentine hemorrhagic fever$957,982
R01 · FY2015 · AI · contact PI
Development of a safe and valid surrogate to study Lassa virus$245,350
R21 · FY2015 · AI · contact PI
Development of a Universal Influenza Vaccine$1,398,670
R01 · FY2014 · AI
Recombinant life attenuated vaccine against Argentine hemorrhagic fever$964,053
R01 · FY2014 · AI · contact PI
Recombinant life attenuated vaccine against Argentine hemorrhagic fever$904,246
R01 · FY2013 · AI · contact PI
Recombinant life attenuated vaccine against Argentine hemorrhagic fever$865,253
R01 · FY2012 · AI · contact PI
Recombinant life attenuated vaccine against Argentine hemorrhagic fever$901,836
R01 · FY2011 · AI · contact PI
Advance Veterinary Services$2,142,856
UC7 · FY2010 · AI · contact PI
Advance Veterinary Services$2,142,856
UC7 · FY2009 · AI · contact PI
Advance Veterinary Services$1,714,285
UC7 · FY2008 · AI · contact PI
Advance Veterinary Services$938,044
UC7 · FY2007 · AI · contact PI
VEE PATHOGENESIS AND VACCINE DEVELOPMENT$118,162
K08 · FY2007 · AI · contact PI
Advance Veterinary Services$172,373
UC7 · FY2006 · AI · contact PI
VEE PATHOGENESIS AND VACCINE DEVELOPMENT$115,349
K08 · FY2006 · AI · contact PI
VEE PATHOGENESIS AND VACCINE DEVELOPMENT$112,619
K08 · FY2005 · AI
VEE PATHOGENESIS AND VACCINE DEVELOPMENT$99,168
K08 · FY2004 · AI